中梁控股(02772.HK)境外債務重組計劃已獲大多數債權人批准
中梁控股(02772.HK)公布,今日(9日)舉行境外債務重組計劃會議,合共510名持有投票計劃債權本金及應計未付利息總額13.27億美元的債權人(佔投票計劃債權未償還總額約96.75%),親身或委任代表出席計劃會議並投票。
於計劃會議中,合共509名持有投票計劃債權本金及應計未付利息總額13.16億美元的債權人(佔在會議投票的投票計劃債權未償還總額約99.12%),投票贊成該計劃。該計劃已獲得所需的大多數計劃債權人批准。
公司將尋求法院對該計劃的批准及裁決。尋求裁決該計劃的呈請將於2月23日聆訊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.